Concert Pharmaceuticals, Inc.
CNCE
CNCE was delisted on the 3rd of March, 2023.
70 hedge funds and large institutions have $127M invested in Concert Pharmaceuticals, Inc. in 2022 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 26 increasing their positions, 9 reducing their positions, and 6 closing their positions.
283% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 6
274% more call options, than puts
Call options by funds: $747K | Put options by funds: $200K
189% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 9
119% more capital invested
Capital invested by funds: $58M → $127M (+$69.2M)
33.54% more ownership
Funds ownership: 49.2% → 82.74% (+34%)
32% more funds holding
Funds holding: 53 → 70 (+17)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$6.57M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$5.44M |
| 3 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$3.96M |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
+$3.37M |
| 5 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$2.95M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$132K |
| 2 |
Charles Schwab
San Francisco,
California
|
-$80K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$61.2K |
| 4 |
Jane Street
New York
|
-$56K |
| 5 |
BlackRock
New York
|
-$49.3K |
CNCE Hedge Fund Activity: Q2 2022 in Review
70 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q2 2022, worth a combined $127M — up 119% from $58M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new CNCE positions and 6 closed out — a net gain of 17 holders — while 26 added to existing stakes and 9 trimmed.
The largest buyer was Nantahala Capital Management, opening a new position worth an estimated $6.57M. The largest seller was Connor, Clark & Lunn Investment Management (CC&L), cutting an estimated $132K.
- 70 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q2 2022, up from 53 in Q1 2022.
- Funds reported $127M of Concert Pharmaceuticals, Inc. stock for Q2 2022, up 119% quarter-over-quarter.
- 23 funds opened new Concert Pharmaceuticals, Inc. positions in Q2 2022 and 6 closed out, a net change of +17 holders.
- The largest Concert Pharmaceuticals, Inc. buyer in Q2 2022 was Nantahala Capital Management, an estimated $6.57M added.
- The largest Concert Pharmaceuticals, Inc. seller in Q2 2022 was Connor, Clark & Lunn Investment Management (CC&L), an estimated $132K sold.
Based on aggregated 13F filings for Q2 2022.